INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,053,824 | -25.1% | 97,021 | -9.0% | 0.01% | -20.0% |
Q2 2023 | $6,751,558 | +14.4% | 106,626 | -2.1% | 0.01% | +11.1% |
Q1 2023 | $5,900,401 | +0.9% | 108,964 | -1.4% | 0.01% | 0.0% |
Q4 2022 | $5,847,448 | +15.1% | 110,496 | +1.2% | 0.01% | 0.0% |
Q3 2022 | $5,082,000 | -19.1% | 109,226 | -0.8% | 0.01% | -10.0% |
Q2 2022 | $6,282,000 | -1.5% | 110,059 | +5.6% | 0.01% | +25.0% |
Q1 2022 | $6,378,000 | +25.8% | 104,232 | +7.6% | 0.01% | +33.3% |
Q4 2021 | $5,069,000 | +43.6% | 96,842 | +2.3% | 0.01% | +20.0% |
Q3 2021 | $3,529,000 | -11.2% | 94,668 | -2.8% | 0.01% | 0.0% |
Q2 2021 | $3,976,000 | +17.1% | 97,406 | -2.6% | 0.01% | +25.0% |
Q1 2021 | $3,395,000 | +6.4% | 100,048 | -0.3% | 0.00% | 0.0% |
Q4 2020 | $3,191,000 | +25.7% | 100,349 | +1.4% | 0.00% | 0.0% |
Q3 2020 | $2,538,000 | +19.2% | 98,925 | +19.3% | 0.00% | 0.0% |
Q2 2020 | $2,129,000 | +72.9% | 82,930 | +3.5% | 0.00% | +33.3% |
Q1 2020 | $1,231,000 | -47.3% | 80,096 | +17.8% | 0.00% | -25.0% |
Q4 2019 | $2,334,000 | +355.9% | 68,016 | -0.8% | 0.00% | +300.0% |
Q3 2019 | $512,000 | -42.5% | 68,579 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $890,000 | +6.6% | 68,579 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $835,000 | +4.5% | 68,579 | -2.3% | 0.00% | 0.0% |
Q4 2018 | $799,000 | -46.3% | 70,173 | +2.4% | 0.00% | -33.3% |
Q3 2018 | $1,487,000 | +22.8% | 68,523 | -0.0% | 0.00% | 0.0% |
Q2 2018 | $1,211,000 | -11.0% | 68,547 | +6.1% | 0.00% | 0.0% |
Q1 2018 | $1,361,000 | +40.5% | 64,636 | -3.4% | 0.00% | +50.0% |
Q4 2017 | $969,000 | +13.6% | 66,902 | +23.8% | 0.00% | 0.0% |
Q3 2017 | $853,000 | +14.7% | 54,025 | -9.8% | 0.00% | 0.0% |
Q2 2017 | $744,000 | -32.2% | 59,865 | -11.4% | 0.00% | 0.0% |
Q1 2017 | $1,098,000 | +2.8% | 67,565 | -4.5% | 0.00% | 0.0% |
Q4 2016 | $1,068,000 | -3.5% | 70,765 | -2.6% | 0.00% | 0.0% |
Q3 2016 | $1,107,000 | -60.4% | 72,665 | +1.0% | 0.00% | -66.7% |
Q2 2016 | $2,794,000 | +77.8% | 71,965 | +27.3% | 0.01% | +100.0% |
Q1 2016 | $1,571,000 | -40.9% | 56,512 | +14.4% | 0.00% | -50.0% |
Q4 2015 | $2,656,000 | +67.8% | 49,381 | +24.9% | 0.01% | +50.0% |
Q3 2015 | $1,583,000 | +25.0% | 39,529 | -0.3% | 0.00% | +33.3% |
Q2 2015 | $1,266,000 | +46.0% | 39,629 | +9.1% | 0.00% | +50.0% |
Q1 2015 | $867,000 | +54.8% | 36,314 | +14.5% | 0.00% | +100.0% |
Q4 2014 | $560,000 | +29.3% | 31,714 | +0.4% | 0.00% | 0.0% |
Q3 2014 | $433,000 | -17.7% | 31,579 | +1.2% | 0.00% | 0.0% |
Q2 2014 | $526,000 | – | 31,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |